rat sglt1

KGA-2727 is a potent and selective SGLT1 inhibitor, with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 for the treatment of diabete.

Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values of 0.8 nM for SGLT2, 23 nM for SGLT1, and 58 nM for DPP4. In diabetic rat models, SGLT2-IN-5 effectively regulates blood glucose and increases the levels of active GLP-1. It is suitable for research on type 2 diabetes.

SGLT2-IN-6 (Compound 101) is an orally active SGLT2 inhibitor with IC₅₀ values of 0.8 nM, 6.7 nM, and 72 nM for SGLT2, SGLT1, and DPP4, respectively. In diabetic rat models, SGLT2-IN-6 controls blood glucose levels and increases active GLP-1 levels. It is suitable for research on type 2 diabetes.

Remogliflozin etabonate (GSK189075A) is a prodrug of regaliflozin and an inhibitor SGLT2 with Ki values of 1.95, 2.14, 8.57, and 43.1μM for hSGLT2, rSGLT2, rSGLT1, and hSGLT1, respectively.